Houston Biotechnology Incorporated

Houston Biotechnology Incorporated was acquired by Medarex, Inc. Houston Biotechnology Incorporated develops biopharmaceutical products for treatment and prevention of common ophthalmic diseases and disorders. Its primary products included an immunotoxin for the prevention of secondary cataract, a common complication following primary cataract surgery. The company was founded in 1984 and is based in The Woodlands, Texas.